{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:22:57Z","timestamp":1760833377816,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":2261,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.breast.2013.07.032","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T13:58:39Z","timestamp":1380290319000},"page":"S165-S170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S2","title":["Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer"],"prefix":"10.1016","volume":"22","author":[{"given":"Rachel C.","family":"Jankowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kandace P.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy E.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2013.07.032_bib1","unstructured":"http:\/\/www.cancer.org\/cancer\/breastcancer\/detailedguide\/breast-cancer-key-statistics [accessed Jan 2013]."},{"key":"10.1016\/j.breast.2013.07.032_bib2","unstructured":"Breast cancer facts and figures 2011\u20132012. http:\/\/www.cancer.org\/research\/cancerfactsfigures\/breastcancerfactsfigures\/breast-cancer-facts-and-figures-2011-2012 [accessed Jan 2013]."},{"key":"10.1016\/j.breast.2013.07.032_bib3","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1200\/JCO.2011.35.8408","article-title":"Improvement in breast cancer outcomes over time: are older women missing out?","volume":"29","author":"Smith","year":"2011","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.breast.2013.07.032_bib4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.07.032_bib5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","article-title":"Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors","volume":"88","author":"Fisher","year":"1996","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.07.032_bib6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2013.07.032_bib7","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(12)62038-8","article-title":"Extended adjuvant tamoxifen for breast cancer-a new era?","volume":"381","author":"Powles","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2013.07.032_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,934 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.032_bib9","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2013.07.032_bib10","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2011.36.4950","article-title":"American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer","volume":"29","author":"Griggs","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.032_bib11","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(07)60778-8","article-title":"Use of luteinising- hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials","volume":"369","author":"Cuzick","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2013.07.032_bib12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1200\/JCO.2005.03.3969","article-title":"Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study","volume":"24","author":"Petrek","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.032_bib13","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1200\/JCO.2002.08.169","article-title":"Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer","volume":"20","author":"Love","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.032_bib14","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/jnci\/94.9.662","article-title":"Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer","volume":"94","author":"Love","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.07.032_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-011-1370-0","article-title":"Effects on survival of menstrual cycle phase of adjuvant surgical oophorectomy in premenopausal women with breast cancer","volume":"126","author":"Love","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.07.032_bib16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2013.07.032_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/annonc\/mds330","article-title":"Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo- controlled NCIC CTG MA17 trial of extended adjuvant letrozole","volume":"24","author":"Goss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.07.032_bib18","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"Ellis","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.032_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12282-010-0239-0","article-title":"Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?","volume":"18","author":"Takei","year":"2011","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2013.07.032_bib20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/92.11.903","article-title":"Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study","volume":"92","author":"Klijn","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.07.032_bib21","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/sj.bjc.6603947","article-title":"Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer","volume":"97","author":"Torrisi","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2013.07.032_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(11)70373-4","article-title":"Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial","volume":"13","author":"Masuda","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2013.07.032_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-010-0794-2","article-title":"Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer","volume":"123","author":"Paridaens","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.07.032_bib24","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.032_bib25","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A\u00a0multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2013.07.032_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2013.07.032_bib27","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","article-title":"Annual hazard rates of recurrence for breast cancer after primary therapy","volume":"14","author":"Saphner","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 8","key":"10.1016\/j.breast.2013.07.032_bib28","doi-asserted-by":"crossref","first-page":"viii18","DOI":"10.1093\/annonc\/mdm262","article-title":"Reducing the risk of late recurrence in hormone-responsive breast cancer","volume":"18","author":"Cufer","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.07.032_bib29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/jnci\/djn233","article-title":"Residual risk of breast cancer recurrence 5 years after adjuvant therapy","volume":"100","author":"Brewster","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.07.032_bib30","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/1471-2164-9-394","article-title":"Comparison of prognostic gene expression signatures for breast cancer","volume":"9","author":"Haibe-Kains","year":"2008","journal-title":"BMC Genomics"},{"year":"2012","series-title":"[P2-10-15] Evaluation of prognostic and predictive performance of breast cancer index and its components in hormonal receptor-positive breast cancer patients","author":"Sgroi","key":"10.1016\/j.breast.2013.07.032_bib31"},{"key":"10.1016\/j.breast.2013.07.032_bib32","unstructured":"Suppression of ovarian function plus either tamoxifen or exemestane compared with tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer (SOFT). [cited 2013 February]; Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00066690."},{"key":"10.1016\/j.breast.2013.07.032_bib33","unstructured":"Triptorelin with either exemestane or tamoxifen in treating premenopausal women with hormone-responsive breast cancer (TEXT). [cited 2013 February]; Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00066703."},{"key":"10.1016\/j.breast.2013.07.032_bib34","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2013.07.032_bib35","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2006.09.4482","article-title":"Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17","volume":"25","author":"Goss","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.032_bib36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10549-011-1801-y","article-title":"Compliance and persistence of endocrine adjuvant breast cancer therapy","volume":"131","author":"Guth","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.07.032_bib37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10549-012-2028-2","article-title":"Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study","volume":"134","author":"van Nes","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.07.032_bib38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10549-011-1578-z","article-title":"Adherence to oral endocrine treatments in women with breast cancer: can it be improved?","volume":"129","author":"Doggrell","year":"2011","journal-title":"Breast Cancer Res Treat"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613001677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613001677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:31:09Z","timestamp":1760776269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977613001677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":38,"alternative-id":["S0960977613001677"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2013.07.032","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2013.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}